- Home
- ACLS vs IRON Comparison
ACLS vs IRON Comparison
Compare ACLS & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACLS
- IRON
- Stock Information
- Founded
- ACLS 1995
- IRON 2017
- Country
- ACLS United States
- IRON United States
- Employees
- ACLS N/A
- IRON N/A
- Industry
- ACLS Industrial Machinery/Components
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- ACLS Technology
- IRON Health Care
- Exchange
- ACLS Nasdaq
- IRON Nasdaq
- Market Cap
- ACLS 1.5B
- IRON 1.4B
- IPO Year
- ACLS 2000
- IRON N/A
- Fundamental
- Price
- ACLS $61.58
- IRON $48.09
- Analyst Decision
- ACLS Buy
- IRON Strong Buy
- Analyst Count
- ACLS 7
- IRON 9
- Target Price
- ACLS $133.00
- IRON $93.89
- AVG Volume (30 Days)
- ACLS 669.2K
- IRON 366.5K
- Earning Date
- ACLS 05-06-2025
- IRON 05-07-2025
- Dividend Yield
- ACLS N/A
- IRON N/A
- EPS Growth
- ACLS N/A
- IRON N/A
- EPS
- ACLS 5.46
- IRON N/A
- Revenue
- ACLS $958,056,000.00
- IRON N/A
- Revenue This Year
- ACLS N/A
- IRON N/A
- Revenue Next Year
- ACLS $7.62
- IRON N/A
- P/E Ratio
- ACLS $11.27
- IRON N/A
- Revenue Growth
- ACLS N/A
- IRON N/A
- 52 Week Low
- ACLS $40.40
- IRON $28.25
- 52 Week High
- ACLS $158.61
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- ACLS 67.66
- IRON 55.80
- Support Level
- ACLS $60.82
- IRON $44.80
- Resistance Level
- ACLS $64.69
- IRON $47.45
- Average True Range (ATR)
- ACLS 2.53
- IRON 3.00
- MACD
- ACLS 1.29
- IRON 0.34
- Stochastic Oscillator
- ACLS 82.88
- IRON 75.05
About ACLS Axcelis Technologies Inc.
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.